Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer

Journal of the National Cancer Institute

Volumn 107, Issue 4, 2015, Pages

  Scurr, Martin J ^a   Brown, Clare M ^a   Costa Bento, Diana F ^a   Betts, Gareth J ^b   Rees, Brian I ^c   Hills, Robert K ^a   Gallimore, Awen ^a,c   Godkin, Andrew ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; TUMOR ANTIGEN; TUMOR ANTIGEN 5T4; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; TROPHOBLASTIC GLYCOPROTEIN 5T4, HUMAN; TUMOR MARKER;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELLULAR IMMUNITY; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; T LYMPHOCYTE; TUMOR RECURRENCE; ADULT; AGED; BLOOD; COLORECTAL NEOPLASMS; FEMALE; IMMUNOLOGY; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERFERON-GAMMA; LYMPHATIC METASTASIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; T-LYMPHOCYTES;

EID: 84930747181     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv001     Document Type: Article

References (19)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352(5):476-487.
3. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-1425.
4. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008;358(25):2698-2703.
5. Chapuis AG, Thompson JA, Margolin KA, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012;109(12):4592-4597.
6. Weide B, Zelba H, Derhovanessian E, et al. Functional T cells targeting NYESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012;30(15):1835-1841.
7. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
8. Davidson BR, Sams VR, Styles J, et al. Comparative study of carcinoembryonic antigen and epithelial membrane antigen expression in normal colon, adenomas and adenocarcinomas of the colon and rectum. Gut. 1989;30(9):1260-1265.
9. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9(2):67-81.
10. Betts G, Jones E, Junaid S, et al. Suppression of tumour-specific CD4(+) T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut. 2012;61(8):1163-1171.
11. Southall PJ, Boxer GM, Bagshawe KD, et al. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61(1):89-95.
12. Clarke SL, Betts GJ, Plant A, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PloS ONE. 2006;1:e129.
13. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127(4):759-767.
14. Turriziani M, Fantini M, Benvenuto M, et al. Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov. 2012;7(3):265-296.
15. Gameiro SR, Jammeh ML, Hodge JW. Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise. Expert Rev Vaccines. 2013;12(6):617-629.
16. Bos R, van Duikeren S, Morreau H, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res. 2008;68(20):8446-8455.
17. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620-626.
18. Grivennikov SI, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature. 2012;491(7423):254-258.
19. Gallimore AM, Godkin A. Epithelial barriers, microbiota, and colorectal cancer. N Engl J Med. 2013;368(3):282-284.